David P. Meeker - 01 Feb 2025 Form 4 Insider Report for RHYTHM PHARMACEUTICALS, INC. (RYTM)

Role
President and CEO, Director
Signature
/s/ Stephen Vander Stoep, Attorney-in-Fact for David Meeker
Issuer symbol
RYTM
Transactions as of
01 Feb 2025
Transactions value $
-$254,242
Form type
4
Filing time
04 Feb 2025, 21:25:31 UTC
Previous filing
29 Aug 2024
Next filing
19 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYTM Common Stock Options Exercise +14.1K +7.84% 194K 01 Feb 2025 Direct F1
transaction RYTM Common Stock Sale -$254K -4.28K -2.2% $59.43 190K 04 Feb 2025 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RYTM Restricted Stock Units Options Exercise $0 -14.1K -33.33% $0.00 28.3K 01 Feb 2025 Common Stock 14.1K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.
F2 The sale reported in this Form 4 was effected pursuant to Rule 10b5-1 instruction adopted prior to February 27, 2023 solely with the intent to cover withholding taxes in connection with the vesting of certain previously reported restricted stock units.
F3 Includes 5,475 additional shares acquired under the Issuer's Employee Stock Purchase Plan.
F4 The restricted stock units vest or have vested as to 25% of the total shares on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The restricted stock units have no expiration date.

Remarks:

Exhibit 24 - Power of Attorney